Skip to main content
. 2022 Sep 26;80(1):64–72. doi: 10.1001/jamaneurol.2022.3018

Table 2. Primary Outcomes, Secondary Outcomes, and Adverse Events.

ITT analysis PP analysis
No. (%) OR (95% CI) No. (%) OR (95% CI)
GA (n = 43) CS (n = 44) Unadjusted P value Adjusteda GA (n = 43) CS (n = 31) Unadjusted P value Adjusteda
mRS score 0-2 at 90 d 21 (48.8) 24 (54.5) 0.80 (0.34-1.85) NA 0.91 (0.37-2.22) 21 (48.8) 19 (61.3) 0.60 (0.24-1.54) NA 0.64 (0.23-1.80)
mRS score at 90 d
Excellent outcome (mRS 0-1) 10 (23.3) 17 (38.6) 0.48 (0.19-1.22) NA 0.58 (0.22-1.53) 10 (23.3) 14 (45.2) 0.37 (0.14-1.00) NA 0.43 (0.15-1.27)
Poor outcome (mRS ≥3) 22 (51.2) 20 (45.5) 1.26 (0.54-2.92) NA 1.10 (.45-2.69) 22 (51.2) 12 (38.7) 1.66 (0.65-4.24) NA 1.56 (0.55-4.38)
Successful reperfusion (mTICI 2b-3) 41 (95.3) 34 (77.3) 6.03 (1.24-29.40) NA 5.86 (1.16-29.53) 41 (95.3) 24 (77.4) 5.98 (1.15-31.14) NA 5.12 (0.94-27.84)
NIHSS score, median (IQR)b
At discharge 5 (3-12) 8 (2-16) NA .68 NA 5 (3-12) 8 (2-16) NA .86 NA
30 d After therapy 2 (1-6) 2 (0-9) NA .60 NA 2 (1-6) 2 (0-7) NA .45 NA
90 d After therapy 1 (1-3) 0 (0-5) NA .23 NA 1 (1-3) 0 (0-2) NA .14 NA
GCS, median (IQR)c
At discharge 15 (12-15) 15 (10-15) NA .95 NA 15 (12-15) 15 (12-15) NA .76 NA
30 d After therapy 15 (14-15) 15 (13-15) NA .94 NA 15 (14-15) 15 (14-15) NA .99 NA
90 d After therapy 15 (15-15) 15 (15-15) NA .48 NA 15 (15-15) 15 (15-15) NA .50 NA
Assisted ventilation 31 (72.1) 18 (40.9) 0.27 (0.11-0.66) NA 0.26 (0.10-0.69) 31 (72.1) 5 (16.1) 0.74 (0.02-0.24) NA 0.06 (0.02-0.23)
Length of assisted ventilation, median (IQR), d 4 (2-7) 7 (3-13) NA .23 NA 4 (2-7) 7 (2-16) NA .53 NA
Length of stay in hospital, median (IQR), d 9 (6-17) 11 (6-15) NA .87 NA 9 (6-17) 12 (6-15) NA .73 NA
Length of stay in the neurological intensive care unit, median (IQR), d 8 (5-15) 9 (4-15) NA .77 NA 8 (5-15) 9 (4-14) NA .70 NA
Mortality
At discharge 5 (11.6) 4 (9.1) 1.32 (0.33-5.27) NA 1.36 (0.33-5.67) 5 (11.6) 1 (3.2) 3.95 (0.44-35.62) NA 4.63 (0.49-43.61)
At 30 d 9 (22.0) 9 (21.4) 1.03 (0.36-2.93) NA 1.05 (0.35-3.14) 9 (22.0) 5 (17.2) 1.35 (0.40-4.55) NA 1.56 (0.42-5.80)
At 90 d 10 (23.3) 9 (20.5) 1.18 (0.43-3.26) NA 1.18 (0.41-3.41) 10 (23.3) 5 (16.1) 1.58 (0.48-5.18) NA 1.81 (0.51-6.44)
Adverse events during treatment
Hypotensiond 23 (53.5) 7 (15.9) 0.17 (0.06-0.45) NA 0.17 (0.06-0.47) 23 (53.5) 3 (9.7) 0.09 (0.03-0.35) NA 0.10 (0.03-0.40)
Dysphoria or motion 1 (2.3) 16 (36.4) 24.00 (2.01-191.36) NA 26.10 (3.14-215.94) 1 (2.3) 5 (16.1) 8.08 (0.89-73.04) NA 7.22 (0.73-70.95)
Complications after EVT
Pulmonary infection 28 (65.1) 20 (45.5) 0.45 (0.19-1.06) NA 0.51 (0.21-1.25) 28 (65.1) 12 (38.7) 0.34 (0.13-0.88) NA 0.44 (0.16-1.22)
Deep venous thrombosis 3 (7.0) 3 (6.8) 0.98 (0.19-5.12) NA 1.06 (0.19-5.90) 3 (7.0) 2 (6.5) 0.92 (0.14-5.86) NA 1.11 (0.16-7.72)
Hemorrhagic transformatione 3 (7.0) 2 (4.5) 0.64 (0.10-4.00) NA 0.42 (0.05-3.48) 3 (7.0) 1 (3.2) 0.44 (0.04-4.49) NA 0.35 (0.02-6.29)

Abbreviations: CS, conscious sedation; EVT, endovascular therapy; GA, general anesthesia; GCS, Glasgow Coma Scale; ITT, intention-to-treat; mTICI, modified treatment in cerebral infarction; mRS, modified Rankin Scale; NA, not applicable; NIHSS, National Institute of Health Stroke Scale; OR, odds ratio; PP, per-protocol.

a

Adjusted odds ratios were estimated using a logistic regression model including age, baseline NIHSS score, occlusion site, and use of IV-tPA.

b

Missing data due to death or dropout. In ITT, data were missing for 4 patients in GA and 4 in CS at discharge, 9 in each group at 30 d, and 10 in GA and 9 in CS at 90 d. In PP, data were missing for 4 patients in GA and 1 in CS at discharge, 9 in GA and 5 in CS at 30 d, and 10 in GA and 5 in CS at 90 d.

c

Missing data due to death or dropout. In ITT, data were missing for 4 patients in GA and 4 in CS at discharge, 9 in each group at 30 d, and 10 in GA and 8 in CS at 90 d. In PP, data were missing for 4 patients in GA and 1 in CS at discharge, 9 in GA and 5 in CS at 30 d, and 10 in GA and 4 in CS at 90 d.

d

Defined as systolic blood pressure <120 mm Hg.

e

Includes symptomatic intracranial hemorrhage, defined as an increase in NIHSS score of >4 points within the first 36 h of stroke onset, and asymptomatic intracranial hemorrhage, defined as an increase in NIHSS score by ≤4 points within the first 36 h of stroke onset.